The team set out to answer a deceptively simple question: which of the EPIC array’s 866,836 CpG probes actually behave as designed? The answer matters because epigenome-wide association studies, or EWAS, depend on the assumption that each probe reliably measures methylation at one specific genomic location. When a probe fails that assumption, the resulting signal can reflect genetic variation, off-target binding, or outright misannotation rather than genuine methylation differences. Such artifacts have plagued earlier Infinium platforms, and previous studies of the 450K and EPIC arrays had already flagged between 6 and 11 percent of all probes as problematic. The Northwestern group extended that work by systematically characterizing the entire EPIC array and, crucially, by asking how the answers change depending on which human population a study examines.

The first stage of the analysis involved mapping every probe sequence back to the human genome reference. This is not as straightforward as it sounds, because the Infinium assay relies on bisulfite conversion, a chemical treatment that converts unmethylated cytosines to uracil, which is read as thymine, while leaving methylated cytosines untouched. To represent all possible post-conversion states, the researchers generated four single-stranded versions of the genome in silico: forward and reverse strands, each in a methylated and unmethylated configuration, with all non-CpG cytosines converted to thymines. A further complication arises with Type II probes, some of which contain ambiguous R nucleotides that can represent either adenine or guanine depending on the methylation state of an internal CpG site. The team replaced every R with all possible A and G combinations, ultimately producing 3,505,864 distinct probe sequences, which they then aligned to the bisulfite-converted reference using the BLAT alignment tool.

The results of this exhaustive mapping exercise were striking. Of the 866,836 probes on the array, 91,034 failed the alignment criteria, which allowed no more than two mismatches and no more than four ambiguous bases, and required a match at the fiftieth nucleotide of each 50-base probe. In other words, roughly one in ten probes did not align reliably to the human genome reference at all. Beyond that, 21,256 probes mapped ambiguously to multiple loci, meaning their signals represent a mixture of genuine methylation at the intended site and spurious signal from elsewhere in the genome. The researchers also compared their mapping results with the original annotations supplied by Illumina and found that 448 probes were assigned to a different gene than the manufacturer’s annotation file claimed, a small but potentially misleading discrepancy for any study interpreting methylation changes in terms of nearby gene regulation.

To understand where the ambiguous probes sit in the functional landscape of the genome, the team performed an enrichment analysis using regulatory element annotations from the ENCODE Analysis Hub at the European Bioinformatics Institute, including DNase I hypersensitivity sites, transcription factor binding sites, and histone modification peaks pooled across cell lines. They compared the observed number of overlaps between ambiguous probes and each regulatory element against a null distribution generated by randomly sampling matched sets of array probes 10,000 times. The ambiguous probes generally followed the genomic distribution of all EPIC probes, but they showed a significant trend of enrichment for H3K9me3, a histone mark associated with constitutive heterochromatin and transcriptionally silent regions, with an empirical p-value below 0.001. This suggests that problematic probes are disproportionately located in compacted, repetitive portions of the genome, precisely where cross-hybridization is most likely to occur.

The second, and arguably more novel, stage of the study examined how common genetic variation within probe sequences varies across human populations. The researchers drew on variant call data from the 1000 Genomes Project, covering 26 global populations organized into five major continental groups: African, European, East Asian, South Asian, and Admixed American. For each bi-allelic SNP in each population, they calculated allele frequencies and then searched the 754,546 unambiguous EPIC probes for common SNPs, defined as those with a minor allele frequency above 0.05, within 20 bases of the interrogated CpG site. This window matters because SNPs near or within the probe sequence can alter hybridization efficiency, causing the measured fluorescence to reflect the genetic variant rather than the methylation state, a phenomenon known as methylation quantitative trait locus confounding when it propagates into association results.

The population-specific findings were pronounced. East Asian populations carried the fewest common SNP-containing probes, 54,810, followed by European populations with 68,155, South Asian with 70,068, Admixed American with 70,576, and African populations with 96,674. That African populations show the highest count is consistent with the well-established observation that genetic diversity is greatest in populations of African ancestry, a legacy of human demographic history. The practical implication is uncomfortable for the field: a probe that performs cleanly in an East Asian cohort may carry a common SNP in an African cohort, and vice versa. Any EWAS conducted in a diverse or non-European population using a single, population-agnostic probe exclusion list risks either discarding usable data or, worse, retaining probes that generate population-specific artifacts that masquerade as epigenetic differences between groups.

To address this, the authors generated a curated list of optimal CpG probes for each major global population, released as supplemental tables alongside the paper. The resource allows investigators to filter their EPIC array results according to the ancestry of their study cohort, excluding probes that are cross-hybridizing, misannotated, or polymorphic in the relevant population. The authors envision a straightforward workflow: researchers who identify differential methylation at any CpG using the EPIC array can cross-reference their hits against this resource to confirm that their findings are not driven by cross-hybridization or by common SNPs specific to the population under study. Given that the supplemental tables enumerate both the problematic probes and the population-specific SNP content of the array, the resource functions as a practical quality-control layer that can be adopted without new experiments.

The broader significance of the study extends beyond a single chip. Methylation arrays remain far more cost-effective than whole-genome bisulfite sequencing for large cohort studies, and they will continue to underpin EWAS in epidemiology, cancer research, aging studies, and environmental epigenetics for years to come. But the field has increasingly recognized that genetic variation and epigenetic variation are entangled, and that interpreting methylation differences between populations without accounting for underlying allele frequency differences can produce spurious conclusions about epigenetic contributions to disease. The Northwestern analysis provides a concrete, quantified demonstration of the scale of that problem on the most widely used current platform, showing that the interplay between probe design and population genetics is not a marginal concern but affects tens of thousands of probes.

For the research community, the message is clear: the EPIC array remains a powerful and efficient tool, but its outputs are only as reliable as the quality control applied to them. Studies of diverse human populations stand to benefit most from the new characterization, since they face the greatest risk of population-specific artifacts. As epigenetic research expands beyond historically overrepresented European cohorts, resources like this probe-level audit will be essential for ensuring that discoveries about the epigenetic roots of complex traits and diseases are genuine, reproducible, and applicable to all of humanity rather than a genetically narrow slice of it.

Subject of Research: Technical characterization of the Illumina EPIC DNA methylation array for population-diverse epigenetic research

Article Title: Characterization of the Illumina EPIC array for optimal applications in epigenetic research targeting diverse human populations

Article References: Zhang, Z., Zeng, C., & Zhang, W. (2022). Characterization of the Illumina EPIC array for optimal applications in epigenetic research targeting diverse human populations. Epigenetics Communications, 2(1), Article 7. https://doi.org/10.1186/s43682-022-00015-9

Image Credits: AI Generated

DOI: 10.1186/s43682-022-00015-9

Keywords: DNA methylation, EPIC array, Illumina, epigenomics, cross-hybridization, single nucleotide polymorphism, 1000 Genomes Project, EWAS, population genetics, probe quality control, bisulfite conversion, genomic annotation

The technique, called qBiCo, is described in the open-access journal Epigenetics Communications. It is a five-plex, TaqMan probe-based quantitative PCR assay that amplifies both single-copy genes and repetitive elements in bisulfite-converted DNA, the modified molecule that nearly every methylation experiment actually measures. From a single reaction, qBiCo estimates four critical parameters: the concentration of converted DNA, its degree of fragmentation, the global conversion efficiency, and the presence of inhibitors that could derail PCR amplification downstream.

The need for such a tool stems from an awkward chemical compromise. Bisulfite conversion works by treating DNA with sodium bisulfite at low pH and elevated temperature, converting unmethylated cytosines into uracils while leaving methylated cytosines untouched. Subsequent PCR replaces the uracils with thymines, so methylation patterns appear as C-to-T sequence variants readable by microarrays, pyrosequencing or massively parallel sequencing. But the same aggressive conditions that perform the conversion also attack the DNA itself. Sodium bisulfite causes depyrimidination and generates abasic sites prone to strand breaks, meaning the treated molecule is fragmented, mostly single-stranded and contaminated with carryover chemicals. Choose gentler conditions and the conversion becomes incomplete, leading to overestimated methylation and misinterpreted data. Choose harsher conditions and the DNA shatters beyond use.

Despite these well-known hazards, most epigenetics researchers have relied on manufacturer promises of greater than 99 percent conversion efficiency, at least 80 percent recovery and eluted fragments up to 2,000 base pairs long. Existing assessment approaches have been piecemeal: Nanodrop spectrophotometry, Qubit fluorometry and Bioanalyzer fragment analysis were never designed for the peculiar, hybrid single- and double-stranded nature of bisulfite-converted DNA. Earlier targeted assays, such as one developed by Ehrich and colleagues, measured fragmentation at increasing incubation temperatures but said nothing about conversion efficiency, while single-locus approaches risked severe bias. None offered a global picture in one test.

The Rotterdam team, led by Athina Vidaki together with Faidra Karkala and colleagues, designed qBiCo around two carefully chosen target classes. A short fragment of the single-copy hTERT gene reports converted DNA concentration, while a longer fragment of the same gene provides a fragmentation index. Two assays target the genomic and converted versions of LINE1, a repetitive element that constitutes roughly 17 percent of the human genome, allowing conversion efficiency to be measured across hundreds of genomic copies rather than a single locus. Because each LINE1 probe interrogates five cytosines across approximately 180 to 200 genomic regions, the efficiency measure is far more representative than comparable systems, such as BisQuE, which relies on a single cytosine in one gene intron. A fifth assay, a spiked-in artificial fragment, acts as an internal positive control flagging PCR inhibition.

Because no reliable standard exists for quantifying converted DNA, the team built synthetic DNA fragments, or gBlocks, mimicking the exact sequences their assays produce, mixed in ratios that resemble natural human converted DNA. Validation showed PCR efficiencies between 90 and 99 percent, linear detection down to picogram quantities, and striking robustness: conversion efficiency readings held steady even in the presence of extremely high levels of the PCR inhibitor hematin. Only artificial DNA degradation, induced by even one minute of UV exposure, meaningfully disturbed the readings.

The real drama came when the researchers applied qBiCo to ten commercial bisulfite conversion kits across DNA inputs ranging from 200 nanograms down to 1 nanogram. Recovery of converted DNA ranged from a sobering 8.5 to 100 percent, and conversion efficiencies from 78 to 99.9 percent, a spread that flatly contradicts the universal promises on the packaging. One kit failed systematically, producing conversion rates as low as 2 percent. Others lost more than 70 percent of the input DNA, while a handful, notably kits from Diagenode, Sigma Aldrich and Qiagen, maintained conversion efficiency above 95 percent even at the lowest inputs. Fragmentation proved pervasive: even with the best-performing kit, the intact portion of DNA fragments at least 235 base pairs long was no more than 50 to 60 percent of the sample, and longer fragments became undetectable at 10-nanogram inputs.

These results echo and extend earlier warnings. A 2018 study by Kint and colleagues had already reported kit recoveries ranging from 26.6 to 88.3 percent using a cumbersome multi-method approach that consumed precious sample. Even the inventor of bisulfite conversion, Hikoya Hayatsu, cautioned in 2008 that available methylation data needed careful re-examination and that a scientifically sound, assured methodology should be established as soon as possible. The qBiCo team argues that the field has, in effect, been running on assumption, and that no bisulfite-converted-DNA-specific method existed until now to hold the process accountable.

Determined to turn the assay into a practical tool, the researchers built an improved prototype, qBiCo-v2. They replaced the weakest assay, a long hTERT fragment, with a 222-base-pair target from the TPT1 gene, halved the reaction volume to 10 microliters, refined the synthetic standard using data from sixteen different conversion kits, and developed a semi-automated spreadsheet pipeline that calculates all four indices directly from raw qPCR output. Crucially, they transferred the method to six qPCR platforms from three major manufacturers, BioRad, Thermo Fisher Scientific and Qiagen, and validated it on each, finding comparable quantification cycles across instruments and establishing a detection limit of 150 picograms of input DNA.

The implications reach well beyond the bench. DNA methylation biomarkers are moving toward clinical implementation in cancer detection, ageing research and forensic science, settings where standardization is paramount and where scarce or degraded samples, such as cell-free tumor DNA or crime-scene traces, make every molecule count. The authors call on epigenetics researchers to shift from assuming their conversion kits work to measuring them empirically, integrating qBiCo as a routine quality-control step regardless of the downstream analysis. If they succeed, a reaction that has quietly shaped two decades of epigenetic data may finally get the scrutiny it has always needed, and the methylation maps of the future could rest on far firmer ground.

Subject of Research: Quality control of bisulfite-converted DNA methylation analysis using quantitative PCR

Article Title: qBiCo: a method to assess global DNA conversion performance in epigenetics via single-copy genes and repetitive elements

Article References: Karkala, F., Simons, R. B., Claessens, F., Kalamara, V., Kayser, M., & Vidaki, A. (2025). qBiCo: a method to assess global DNA conversion performance in epigenetics via single-copy genes and repetitive elements. Epigenetics Communications, 5(1), Article 2. https://doi.org/10.1186/s43682-025-00033-3

Image Credits: AI Generated

DOI: 10.1186/s43682-025-00033-3

Keywords: DNA methylation, bisulfite conversion, epigenetics, qPCR, quality control, LINE1, hTERT, DNA fragmentation, biomarkers, forensics, kit validation, standardization

Down syndrome, caused in about 95 percent of cases by a full extra copy of chromosome 21, is the most common chromosomal disorder associated with intellectual disability. Its effects ripple across the neurological, musculoskeletal, and cardiovascular systems, and roughly half of all individuals with the condition are born with congenital heart defects. Over the past decade, researchers have documented widespread epigenetic alterations, changes to chemical marks on DNA that regulate gene activity without altering the underlying sequence, in the nuclear DNA of people with trisomy 21. These changes have been linked to features ranging from accelerated aging to hematological and cardiovascular complications. But the mitochondrial genome has remained largely terra incognita for epigeneticists, even as evidence accumulates that mitochondrial dysfunction is a genuine feature of the syndrome.

The reason mitochondria matter so much in Down syndrome comes down to gene dosage. The extra chromosome carries genes involved in oxidative stress pathways, and cells from people with the syndrome show impaired energy metabolism, chronic pro-oxidative states, and deficits in the molecular machinery that produces ATP, the cell’s energy currency. Studies in fibroblasts and brain tissue have repeatedly detected these functional disturbances. Yet measuring mitochondrial function directly is difficult, and one of the most accessible molecular proxies, the number of mitochondrial DNA copies per cell, has yielded only slight and statistically unconvincing increases in prior studies of Down syndrome tissues.

The new study focused on a very specific stretch of the mitochondrial genome: the D-loop, a non-coding regulatory region that contains both the origin of DNA replication and the main transcription start site for the mitochondrial chromosome. The D-loop is where DNA methyltransferases, the enzymes that attach methyl groups to cytosine bases, appear to concentrate their activity on mitochondrial DNA. Although methylation levels across the mitochondrial genome are typically very low, around 0.5 to 1 percent, the D-loop can reach peaks of 10 to 15 percent. Crucially, methylation in this region modulates the binding of TFAM, mitochondrial transcription factor A, a master regulator of both mitochondrial DNA transcription and replication. In diseases from Alzheimer’s to amyotrophic lateral sclerosis to cardiovascular conditions, D-loop methylation has been found altered and sometimes correlated with disease severity and mitochondrial DNA copy number, making it a plausible suspect in Down syndrome as well.

The suspicion was sharpened by a single earlier study from 2011, in which researchers examined immortalized lymphoblastoid cells from six children with Down syndrome and six matched controls. That work identified a breakdown in one-carbon metabolism, the cellular circuit that generates the methyl-donor molecule S-adenosylmethionine, and found reduced levels of this methylating agent inside the mitochondria of Down syndrome cells, along with global hypomethylation of mitochondrial DNA. If mitochondrial methylation capacity was genuinely compromised, it stood to reason that measurable differences should appear in patient blood samples.

To find out, the team led by Andrea Stoccoro and Fabio Coppedè of the University of Pisa, working with colleagues at the University of Rijeka and the Juraj Dobrila University of Pula, recruited 118 participants at the Clinical Hospital Centre Rijeka in collaboration with Down syndrome associations across Croatia. The cohort ranged in age from newborns to 55 years, with every Down syndrome case confirmed by karyotyping and every participant matched by age and sex to a healthy control. Among the newborns, ten had Down syndrome with congenital heart defects, eight had Down syndrome without such defects, and eighteen were healthy controls. The heart defects identified by ultrasound included five atrial septal defects, two atrioventricular septal defects, one ventricular septal defect, one patent ductus arteriosus, and one case of tetralogy of Fallot, and newborn blood samples were drawn within seventy-two hours of birth, before any surgical or medical correction of cardiac malformations could confound the measurements.

Methodologically, the study leaned on methylation-sensitive high-resolution melting, a technique that amplifies a bisulfite-converted segment of DNA and then reads out its methylation level from the melting behavior of the resulting PCR product. The team had previously developed and validated this protocol against pyrosequencing, and in the present study it targeted a 222-base-pair segment of the D-loop containing ten CpG sites. Calibration standards spanning 0 to 100 percent methylation were run in each assay, and an interpolation method developed in the same laboratory converted melting curves into precise single-value methylation percentages. Bisulfite conversion efficiency averaged 99 percent, and equal numbers of patient and control samples were processed together to suppress batch effects. Mitochondrial DNA copy number was measured independently by quantitative PCR comparing a mitochondrial target against the nuclear hemoglobin beta gene, with the caveat that limited DNA availability allowed copy number analysis in only 103 of the 118 participants.

The results were striking in their uniformity. Across individuals, D-loop methylation ranged from 0 to about 8 percent, and mitochondrial DNA copy number ranged from 33 to 900 copies, reflecting enormous person-to-person variability. But the distributions overlapped almost perfectly between groups. Median D-loop methylation was 1.3 percent in controls versus 4.0 percent in the Down syndrome group, a difference that fell short of statistical significance at p equal to 0.28. Mitochondrial DNA copy number medians were similarly indistinguishable, at roughly 128 copies in controls and 149 in the syndrome group, with p equal to 0.22. Age showed no correlation with either biomarker across the entire sample, spanning newborns to mid-adulthood. Sex made no significant difference either, although the authors noted a slight, non-significant tendency toward higher copy number in males. Most importantly for the congenital heart question, comparisons among the three newborn groups, those with Down syndrome and heart defects, those with Down syndrome and healthy hearts, and controls, revealed no differences in either methylation or copy number, with p values of 0.85 and 0.60 respectively.

The authors are careful to frame the work as a pilot study and to spell out its limits. The analysis covered only a small portion of the mitochondrial genome, so alterations elsewhere in the mitochondrial chromosome cannot be excluded. The newborn subgroup, particularly those without heart defects, was small, and too small to permit sex-stratified analysis even though previous genome-wide studies of nuclear DNA in Down syndrome newborns have shown that many methylation differences tied to congenital heart defects are sex-specific. Blood methylation may also simply fail to mirror what happens in fetal cardiac tissue, the site where the relevant biology would actually unfold. Larger cohorts and studies of cardiac tissue itself will be needed before mitochondrial methylation can be definitively ruled out in the syndrome’s cardiovascular complications.

Even so, the null result carries a useful message. It suggests that the mitochondrial dysfunction documented in Down syndrome, including the more pronounced oxidative stress seen in fetuses with congenital heart defects, does not register in the two most accessible mitochondrial molecular readouts available from a routine blood sample. Unlike nuclear DNA methylation, where robust signatures of trisomy 21 have been detected in blood, placenta, buccal cells, brain, and myocardial tissue, the mitochondrial D-loop appears to hold steady. For researchers hunting biomarkers that could distinguish Down syndrome newborns with heart defects from those without, the message is that the mitochondrial D-loop is unlikely to provide one, at least not in peripheral blood. For the broader field of mitochondrial epigenetics, the study adds a well-controlled data point to a growing literature showing that D-loop methylation shifts in some neurological and cardiovascular diseases but not in every condition marked by mitochondrial stress, a reminder that in biology, the absence of a signal can be as informative as its presence.

Subject of Research: Mitochondrial D-loop region methylation and mitochondrial DNA copy number in individuals with Down syndrome

Article Title: Analysis of mitochondrial D-loop region methylation and copy number in peripheral blood DNA of Down syndrome individuals including newborns with and without congenital heart defects

Article References: Analysis of mitochondrial D-loop region methylation and copy number in peripheral blood DNA of Down syndrome individuals including newborns with and without congenital heart defects. (n.d.). https://doi.org/10.1186/s43682-025-00039-x

Image Credits: AI Generated

DOI: 10.1186/s43682-025-00039-x

Keywords: Down syndrome, mitochondrial DNA, D-loop methylation, mtDNA copy number, epigenetics, congenital heart defects, trisomy 21, bisulfite conversion, high-resolution melting, mitochondrial dysfunction, newborns, biomarkers